Australia's most trusted
source of pharma news
Posted 20 November 2025 AM
Almost half of the 22 changes to existing listings that the PBAC will consider in March are to add a new cancer or other new indication, with ten drugs looking to expand into new diseases.
Two pharmas are seeking funding for the interleukin blockers to treat chronic obstructive pulmonary disease. Sanofi's Dupixent will be considered for use as add-on maintenance treatment for uncontrolled COPD in adult patients with raised blood eosinophils and on a stable combination of drugs, while GSK's Nucala will be considered for use in combination with other drugs for the treatment of adult patients with COPD characterised by an eosinophilic phenotype who continue to experience exacerbations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.